Costs, length of stay, and mortality of super‐refractory status epilepticus: A population‐based study from Germany
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Summary: Objective: Super‐refractory status epilepticus (SRSE) is a severe condition in which a patient in status epilepticus (SE) for ≥24 h does not respond to first‐, second‐, or third‐line therapy. The economic impact of SRSE treatment remains unclear. A health insurance research database was used for a population‐based estimation of SRSE‐associated inpatient costs, length of stay, and mortality in Germany. Methods: An algorithm using International Classification of Diseases, 10th Edition coding and treatment parameters identified and classified patients in a German statutory health insurance database covering admissions from 2008 to 2013 as having refractory SE (RSE) or SRSE. Admissions data in our study refer to these classifications. Associated patient data included costs, procedures, and demographics. Results: The algorithm identified 2,585 (all type) SE admissions, classified as 1,655 nonrefractory SE (64%), 592 (22.9%) RSE, and 338 (13.1%) SRSE, producing database incidence rates of 15.0 in 100,000, 5.2 in 100,000, and 3.0 in 100,000 per year, respectively. Median cost per admission was €4,063 for nonrefractory SE, €4,581 (p < 0.001) for RSE, and €32,706 (p < 0.001) for SRSE. Median length of stay varied significantly between 8 days (mean = 13.6) in nonrefractory SE, 14 days in RSE, and up to 37 days in SRSE. Discharge mortality increased from 9.6% in nonrefractory SE to 15.0% (p < 0.001) in RSE and 39.9% (p < 0.001) in SRSE. Significance: This study evaluated the hospital treatment costs associated with admissions classified by the algorithm as SRSE in Germany. SRSE represented 13% of all SE admissions, but resulted in 56% of all SE‐related costs. The lack of approved treatments and limited number of evidence‐based treatment guidelines highlight the need for further evaluations of the SRSE burden of illness and the potential for further optimization of treatments for SRSE.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trinka, E., Cock, H., Hesdorffer, D., Rossetti, A. O., Scheffer, I. E., Shinnar, S., Shorvon, S., & Lowenstein, D. H. (2015) · Epilepsia · doi:10.1111/epi.13121 · Cited by 2,494 · cited 3×
“The 2015 International League Against Epilepsy (ILAE) guidelines define SE as a seizure lasting >5 min (generalized convulsive SE), ≥10 min (focal SE), or repeated seizures that do not permit recovery to baseline between events.(1) If left untreated, SE can lead to profound long-term effects through excitotoxic neuron…”
BackgroundResultRecommendations for optimal ICD codes to study neurologic conditions: A systematic review
St. Germaine-Smith, C., Metcalfe, A., Pringsheim, T., Roberts, J. I., Beck, C. A., Hemmelgarn, B. R., McChesney, J., Quan, H., & Jette, N. (2012) · Neurology · doi:10.1212/wnl.0b013e3182684707 · Cited by 206
Cited by
Kienitz, R., Kay, L., Beuchat, I., Gelhard, S., von Brauchitsch, S., Mann, C., Lucaciu, A., Schäfer, J.-H., Siebenbrodt, K., Zöllner, J.-P., et al. (2022) · CNS Drugs · doi:10.1007/s40263-022-00940-2 · Cited by 139
Self-citation
Metadata
- Authors
- Strzelczyk, A., Ansorge, S., Hapfelmeier, J., Bonthapally, V., Erder, M. H., & Rosenow, F.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2017-07-06
- Volume
- 58
- Issue
- 9
- Pages
- 1533-1541
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W2730221123
- Cited by
- 192
- References
- 2
- FWCI
- 15.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.